Susie A Hales1, Martina Di Simplicio2, Lalitha Iyadurai3, Simon E Blackwell4, Kerry Young5, Christopher G Fairburn3, John R Geddes6, Guy M Goodwin7, Emily A Holmes8. 1. Oxford Institute of Clinical Psychology Training,Oxford,UK. 2. Centre for Psychiatry,Brain Sciences Division,Imperial College London,London,UK. 3. Department of Psychiatry,University of OxfordandOxford Health NHS Foundation Trust,UK. 4. Ruhr Universität-Bochum,Bochum,Germany. 5. Central and North West London NHS Foundation Trust,UK. 6. Department of Psychiatry,University of Oxford;NIHR Oxford Health Biomedical Research Centre and Oxford Health NHS Foundation Trust,UK. 7. Department of Psychiatry,University of Oxford and Oxford Health NHS Foundation Trust,UK. 8. Division of Psychology,Department of Clinical Neuroscience,Karolinska Institutet,Stockholm,Sweden.
Abstract
BACKGROUND: Despite the global impact of bipolar disorder (BD), treatment success is limited. Challenges include syndromal and subsyndromal mood instability, comorbid anxiety, and uncertainty around mechanisms to target. The Oxford Mood Action Psychology Programme (OxMAPP) offered a novel approach within a cognitive behavioural framework, via mental imagery-focused cognitive therapy (ImCT). AIMS: This clinical audit evaluated referral rates, clinical outcomes and patient satisfaction with the OxMAPP service. METHOD: Eleven outpatients with BD received ImCT in addition to standard psychiatric care. Mood data were collected weekly from 6 months pre-treatment to 6 months post-treatment via routine mood monitoring. Anxiety was measured weekly from start of treatment until 1 month post-treatment. Patient feedback was provided via questionnaire. RESULTS: Referral and treatment uptake rates indicated acceptability to referrers and patients. From pre- to post-treatment, there was (i) a significant reduction in the duration of depressive episode relapses, and (ii) a non-significant trend towards a reduction in the number of episodes, with small to medium effect size. There was a large effect size for the reduction in weekly anxiety symptoms from assessment to 1 month follow-up. Patient feedback indicated high levels of satisfaction with ImCT, and underscored the importance of the mental imagery focus. CONCLUSIONS: This clinical audit provides preliminary evidence that ImCT can help improve depressive and anxiety symptoms in BD as part of integrated clinical care, with high patient satisfaction and acceptability. Formal assessment designs are needed to further test the feasibility and efficacy of the new ImCT treatment on anxiety and mood instability.
BACKGROUND: Despite the global impact of bipolar disorder (BD), treatment success is limited. Challenges include syndromal and subsyndromal mood instability, comorbid anxiety, and uncertainty around mechanisms to target. The Oxford Mood Action Psychology Programme (OxMAPP) offered a novel approach within a cognitive behavioural framework, via mental imagery-focused cognitive therapy (ImCT). AIMS: This clinical audit evaluated referral rates, clinical outcomes and patient satisfaction with the OxMAPP service. METHOD: Eleven outpatients with BD received ImCT in addition to standard psychiatric care. Mood data were collected weekly from 6 months pre-treatment to 6 months post-treatment via routine mood monitoring. Anxiety was measured weekly from start of treatment until 1 month post-treatment. Patient feedback was provided via questionnaire. RESULTS: Referral and treatment uptake rates indicated acceptability to referrers and patients. From pre- to post-treatment, there was (i) a significant reduction in the duration of depressive episode relapses, and (ii) a non-significant trend towards a reduction in the number of episodes, with small to medium effect size. There was a large effect size for the reduction in weekly anxiety symptoms from assessment to 1 month follow-up. Patient feedback indicated high levels of satisfaction with ImCT, and underscored the importance of the mental imagery focus. CONCLUSIONS: This clinical audit provides preliminary evidence that ImCT can help improve depressive and anxiety symptoms in BD as part of integrated clinical care, with high patient satisfaction and acceptability. Formal assessment designs are needed to further test the feasibility and efficacy of the new ImCT treatment on anxiety and mood instability.
Authors: Martine Vallarino; Chantal Henry; Bruno Etain; Lillian J Gehue; Craig Macneil; Elizabeth M Scott; Angelo Barbato; Philippe Conus; Stefanie A Hlastala; Mary Fristad; David J Miklowitz; Jan Scott Journal: Lancet Psychiatry Date: 2015-05-27 Impact factor: 27.083
Authors: Steven Jones; Elly McGrath; Kay Hampshire; Rebecca Owen; Lisa Riste; Chris Roberts; Linda Davies; Debbie Mayes Journal: BMC Psychiatry Date: 2013-02-15 Impact factor: 3.630
Authors: G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young Journal: J Psychopharmacol Date: 2016-03-15 Impact factor: 4.153
Authors: Martina Di Simplicio; Alex Lau-Zhu; Iselin Meluken; Patrick Taylor; Lars Vedel Kessing; Maj Vinberg; Emily Alexandra Holmes; Kamilla Woznica Miskowiak Journal: Front Psychiatry Date: 2019-11-08 Impact factor: 4.157